A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT06891560
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Enfortumab Vedotin — DRUGintravenously on Days 1, 8 and 15 of a 28-day cycle-dose can be done up to +/-3 days after the scheduled day of administration
Study Details
The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).
Key Dates
- Start date
- Mar 31, 2025
- Status verified
- Mar 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 34 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Enfortumab VedotinParticipants are treated with enfortumab vedotin at the FDA-approved dose and schedule of intravenously on Days 1, 8 and 15 of a 28-day cycle.
Primary Outcome Measure
best overall response rate [ Time Frame: 1 year ]
Central Contacts
- Alan Ho, MD, PhD646-541-7062
- Winston Wong, MD646-608-4245
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge | New Jersey | 07920 | Alan Ho, MD. PhD 646-541-7062 |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown | New Jersey | 07748 | Alan Ho, MD, PhD 646-541-7062 |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale | New Jersey | 07645 | Alan Ho, MD, PhD 646-541-7062 |
| Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) | Commack | New York | 11725 | Alan Ho, MD, PhD 646-541-7062 |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison | New York | 10604 | Alan Ho, MD, PhD 646-541-7062 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Alan Ho, MD. PhD 646-541-7062 Winston Wong, MD 646-608-4245 Alan Ho, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale | New York | 11553 | Alan Ho, MD, PhD 646-541-7062 |
Find similar trials in Basking Ridge, NJ
By research site
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (All Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (All Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (All Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY
Related Studies
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- A Study of XMT-1660 in Participants With Solid TumorsPHASE1 · Recruiting · Mersana Therapeutics · Phoenix, Arizona
- Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic CarcinomaPHASE1/PHASE2 · Recruiting · Remix Therapeutics · San Francisco, California
- Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)PHASE1 · Recruiting · Rgenta Therapeutics Inc · Boston, Massachusetts